Tanja D. de Gruijl
Papers
1
Total Citations
13
H-Index
1
About
Tanja D. de Gruijl is a leading translational immunologist whose research sits at the intersection of cancer immunotherapy and interventional oncology. Her primary focus is on understanding and manipulating the tumor microenvironment to overcome immune suppression, particularly in prostate cancer. In her landmark IRE-IMMUNO study (2024), she demonstrated that irreversible electroporation (IRE)—a focal ablation technique—not only destroys prostate tumors but actively downregulates local immune suppression and induces systemic anti-tumor T-cell activation. This groundbreaking work, already garnering 13 citations, positions IRE as a powerful in situ vaccine that can synergize with checkpoint inhibitors. De Gruijl’s broader contributions include pioneering strategies to harness dendritic cells and T cells for adoptive therapy, and elucidating mechanisms of immune escape in solid tumors. Her work has profound implications for turning locally ablative therapies into systemic immunotherapies, offering new hope for patients with intermediate-risk prostate cancer. With a career marked by high-impact publications and collaborative clinical trials, de Gruijl continues to shape the future of cancer treatment by bridging the gap between local tumor destruction and durable systemic immunity.
Research Focus
Key Achievements
Top Papers
- 1